Intelligence Profile
Research Papers
Research on human mesenchymal stem cells (MSCs) is advancing in a variety of medical contexts, exploring their potential for regeneration and disease treatment.
A recent pilot study examined the use of nebulized 3D-cultured MSC-derived extracellular vesicles to treat post-COVID-19 chronic cough. Although details on sample size and outcomes are not provided here, the study suggests potential for respiratory therapy.
For skeletal applications, one study looked at Mn-Icariin-functionalized hydrogels using MSCs for diabetic bone regeneration, highlighting a novel approach to restoring bone health by managing oxidative stress and supporting bone vascularization.
In osteoarthritis, an early phase clinical trial (NCT06082440) is investigating the safety and tolerance of using MSCs mediated by arthroscopy, suggesting ongoing exploration into joint repair.
Liver cirrhosis is another target, with a Phase 2 trial (NCT03945487) assessing MSC treatment for decompensated liver conditions, though outcomes remain unspecified.
In neurological disorders, an ongoing Phase 1/2 trial (NCT01360164) is evaluating the safety and efficacy of umbilical cord MSC therapy for hereditary ataxia, while another trial (NCT02283879) focuses on using MSCs for cerebral hemorrhage sequelae.
Cancer and tissue repair are also areas of interest. Studies like the one on bone marrow MSC exosomes in osteonecrosis explore pathological mechanisms, and serum-free expanded hair follicle MSCs have shown potential in cartilage repair in animal models.
Overall, while promising, much of the research is still in early phases, and detailed results are necessary to validate the therapies' effectiveness and safety. Future studies and completed clinical trials will be critical in confirming the therapeutic potential of MSCs across these diverse conditions.
Disclaimer: This summary is for informational purposes only and not intended as medical advice. Consult healthcare professionals for personal medical decisions.